Log in

NASDAQ:MRUSMerus Stock Price, Forecast & News

$12.99
-0.19 (-1.44 %)
(As of 08/11/2020 04:00 PM ET)
Add
Compare
Today's Range
$12.86
Now: $12.99
$13.35
50-Day Range
$13.23
MA: $14.58
$16.65
52-Week Range
$10.19
Now: $12.99
$20.95
Volume43,294 shs
Average Volume107,315 shs
Market Capitalization$377.26 million
P/E RatioN/A
Dividend YieldN/A
Beta0.66
Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers. The company is also developing MCLA-117 that is in Phase I clinical trial for the treatment of patients with acute myeloid leukemia; and MCLA-158, which is in a Phase I clinical trial for treating metastatic colorectal cancer. In addition, its preclinical development stage bispecific antibody candidates include MCLA-145, which is being developed in collaboration with Incyte Corporation; and other preclinical candidates in various stages of development. Merus N.V. has collaboration with the Integral Molecular for discovering MAbs against structurally complex proteins; and Lipoparticles, virus-like particles displaying high concentrations of membrane proteins. The company was founded in 2003 and is headquartered in Utrecht, the Netherlands.
Read More
Merus logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.97 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MRUS
CUSIPN/A
Phone31-0-30-253-8800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$31.13 million
Book Value$5.61 per share

Profitability

Net Income$-55,150,000.00
Net Margins-243.85%

Miscellaneous

Employees98
Market Cap$377.26 million
Next Earnings Date11/10/2020 (Estimated)
OptionableNot Optionable
$12.99
-0.19 (-1.44 %)
(As of 08/11/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MRUS News and Ratings via Email

Sign-up to receive the latest news and ratings for MRUS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Merus (NASDAQ:MRUS) Frequently Asked Questions

How has Merus' stock been impacted by COVID-19 (Coronavirus)?

Merus' stock was trading at $14.54 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, MRUS shares have decreased by 10.7% and is now trading at $12.99.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Merus?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merus in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Merus
.

When is Merus' next earnings date?

Merus is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Merus
.

What price target have analysts set for MRUS?

3 equities research analysts have issued 12 month target prices for Merus' stock. Their forecasts range from $16.00 to $23.00. On average, they anticipate Merus' stock price to reach $20.67 in the next year. This suggests a possible upside of 59.1% from the stock's current price.
View analysts' price targets for Merus
.

Has Merus been receiving favorable news coverage?

News coverage about MRUS stock has been trending somewhat positive recently, InfoTrie reports. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Merus earned a media sentiment score of 1.0 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days.
View the latest news about Merus
.

Are investors shorting Merus?

Merus saw a decline in short interest in February. As of February 15th, there was short interest totaling 311,000 shares, a decline of 15.6% from the January 31st total of 368,500 shares. Based on an average daily volume of 80,800 shares, the short-interest ratio is currently 3.8 days. Currently, 1.5% of the company's stock are short sold.
View Merus' Short Interest
.

Who are some of Merus' key competitors?

What other stocks do shareholders of Merus own?

Who are Merus' key executives?

Merus' management team includes the following people:
  • Dr. Ton Logtenberg, Pres, CEO, Principal Financial Officer & Exec. Director (Age 61)
  • Dr. Hennie Hoogenboom Ph.D., Co-Founder and Scientific Advisor
  • Ms. Jillian Connell, VP of Investor Relations & Corp. Communications
  • Mr. John de Kruif Ph.D., CTO & Sr. VP (Age 55)
  • Mr. Mark Throsby Ph.D., Chief Scientific Officer & Exec. VP (Age 52)

When did Merus IPO?

(MRUS) raised $64 million in an initial public offering (IPO) on Thursday, May 19th 2016. The company issued 4,300,000 shares at $14.00-$16.00 per share. Citigroup and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers.

What is Merus' stock symbol?

Merus trades on the NASDAQ under the ticker symbol "MRUS."

Who are Merus' major shareholders?

Merus' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Platinum Investment Management Ltd. (0.66%), Alps Advisors Inc. (0.14%) and Swiss National Bank (0.12%). Company insiders that own Merus stock include Bvf Partners L P/Il, Mark Throsby and Value Fund L P Biotechnology.
View institutional ownership trends for Merus
.

Which major investors are selling Merus stock?

MRUS stock was sold by a variety of institutional investors in the last quarter, including Platinum Investment Management Ltd., and Alps Advisors Inc..
View insider buying and selling activity for Merus
.

Which major investors are buying Merus stock?

MRUS stock was bought by a variety of institutional investors in the last quarter, including Swiss National Bank. Company insiders that have bought Merus stock in the last two years include Bvf Partners L P/Il, and Value Fund L P Biotechnology.
View insider buying and selling activity for Merus
.

How do I buy shares of Merus?

Shares of MRUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Merus' stock price today?

One share of MRUS stock can currently be purchased for approximately $12.99.

How big of a company is Merus?

Merus has a market capitalization of $377.26 million and generates $31.13 million in revenue each year. The biotechnology company earns $-55,150,000.00 in net income (profit) each year or ($2.33) on an earnings per share basis. Merus employs 98 workers across the globe.

What is Merus' official website?

The official website for Merus is www.merus.nl.

How can I contact Merus?

Merus' mailing address is YALELAAN 62, UTRECHT P7, 3584 CM. The biotechnology company can be reached via phone at 31-0-30-253-8800 or via email at [email protected]

This page was last updated on 8/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.